HUTCHMED Nears EU Approval for Cancer Drug
Company Announcements

HUTCHMED Nears EU Approval for Cancer Drug

Hutchmed (China) Limited (HCM) has released an update.

HUTCHMED’s partner Takeda has received a positive CHMP opinion for fruquintinib, a potential new metastatic colorectal cancer treatment in the EU, marking a significant step towards marketing authorization. This recommendation is based on the FRESCO-2 Phase III clinical trial results and, if approved, fruquintinib will be the first novel targeted therapy for this condition in the EU in over a decade. Fruquintinib, having shown a profound impact on patients in China and the U.S., now awaits the European Commission’s final decision.

For further insights into HCM stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyHutchmed announces new, updated data from sovleplenib ESLIM-01 trial
TheFlyHutchmed to receive $20M milestone payment from Takeda for Fruzaqla sales
TheFlyHutchmed announces results from SAVANNAH trial
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App